Business Wire

Elon Musk Talks ‘Tech Support’ Governance as World Leaders Champion Innovation-Driven Reforms at Dubai Summit

14.2.2025 16:57:00 CET | Business Wire | Press release

Share

Wearing a “Tech Support”-printed T-shirt, Elon Musk virtually took to the stage on the final day of the World Governments Summit in a live discussion with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications, to share his vision for improving government efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214293771/en/

Elon Musk in conversation with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications (Photo: Business Wire)

Musk emphasized the urgency of streamlining operations, advocating for smaller, more accountable institutions to drive efficiency and economic growth.

The World Governments Summit, held in Dubai from February 11-13, brought together global leaders and experts to address critical challenges in governance, healthcare, and trade in the 21st century.

Now in its 12th edition, the Summit unveiled a suite of insights, key results, and actionable solutions developed by top policymakers, innovators, and thought leaders from around the world.

Musk stated: “We have the rule of bureaucracy as opposed to the rule of the people” and advocated for cutting regulations and government spending to stimulate economic growth, aiming for 4-5% growth without inflation by 2026.

“The overarching goal is to lay the foundation for prosperity that will last many decades, maybe centuries,” Musk added. He stressed the importance of updating government technology, noting that many systems are outdated and inefficient, such as the manual pension system. “The U.S. government needs tech support,” he quipped.

On foreign policy, Musk stated, “America should mind its own business rather than push for regime change,” signaling a shift towards less international interference. He also stressed the need to improve basic education, pointing out the U.S.’s low ranking in the OECD.

Musk also discussed Grok 3.0, his latest AI model set to launch in 1-2 weeks, calling it “scary smart.” He added, “This might be the last time any AI is better than Grok.”

Meanwhile, Joseph Tsai, Chairman of Alibaba Group, a user and admirer of Grok, argued that the value of AI isn’t in having the smartest systems, but in their application in solving real-world problems.

He compared AI development to raising children, emphasizing that not everyone needs the “smartest child.” He predicts that more resources will shift towards practical applications, leveraging open-source tools, which democratize AI development. He added: “Companies big and small can now develop AI together and contribute to the power of AI.”

Beyond AI, both Arvind Krishna, CEO of IBM, and Sundar Pichai, CEO of Google, said they looked forward to the imminent age of quantum computing, which they believe will spearhead the world into a new era.

Pichai said: “Google’s quantum computing performed a computation in five minutes that would take the fastest supercomputer over 10 septillion years.” He compared its current state to AI in the 2010s, predicting practical applications within 5-10 years.

Pichai added that for governments: “It’s too early to regulate the technology, but I think it’s important to come to a good understanding of it and then start preparing for it.”

Technology as the enabler of the new age of healthcare and education

Public healthcare systems also require innovation and new policies, argued experts at the Summit. Addressing key challenges in healthcare, Pascal Soriot, CEO of AstraZeneca, encouraged governments to develop policies that enable early disease diagnostics, improve accessibility, and encourage population-wide adoption.

Soriot stated: “Seventy-five percent of deaths come from diseases that are preventable, yet governments only spend 3% of healthcare budgets on prevention and early diagnosis.” He added that diagnostic centers should run 24/7 to reduce costs and increase accessibility.

He highlighted AI’s role in transforming healthcare, noting that it is already enhancing early diagnostics, such as lung cancer detection from X-rays, and improving efficiency in drug development. While skepticism exists around AI's role in drug design due to limited biological data, its potential in healthcare is promising.

“We are not far away from the days when a simple blood test would enable early diagnostics of cancer at a relatively low cost,” Soriot concluded.

Public-private partnerships and innovative healthcare models could further improve accessibility and cost-efficiency, helping transform global healthcare systems.

This applies beyond just healthcare. Mike Sicilia, Executive Vice President of Oracle, stated: “At the heart of every AI strategy is a data strategy. Helping governments vectorize and aggregate the data is the first step in applied AI, particularly when tailoring it to specific citizen services.”

AI applications in education were also a major focus at the Summit. David Baszucki, CEO of Roblox, explored the potential of AI in educating young users through interactive experiences on the platform. He also emphasized the importance of balancing social connectivity and safety on digital platforms.

He added: “We are at a place where it is way beyond what we imagined. In 20 years, I’m expecting an amazing amount of learning on the platform—for instance, interacting with virtual historical characters.”

Global economic challenges and financial cooperation

In parallel discussions, Kristalina Georgieva, Managing Director of the IMF, alongside finance ministers, international officials, and economic experts, explored the challenges facing the multilateral cooperation system, including rising nationalist and geopolitical trends, climate change, and economic inequality.

Speakers highlighted the need for innovative financing mechanisms and an expanded global financial safety net to address economic crises and support developing countries.

They also underlined the role of technology in strengthening financial systems, aligning global networks to protect against economic crises, and building sustainable frameworks for debt management in vulnerable economies.

For more information, visit worldgovernmentsummit.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250214293771/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye